PROJECT GOLD
LIVE

Serial Number

98160589

Owner

Curae Pharma360 Inc.

Attorney

Andrew D. Bochner

Filing Date

Sep 1, 2023

Add to watchlist:

No watchlists yet
View on USPTO

PROJECT GOLD Trademark

Serial Number: 98160589 • Registration: 7584273

PROJECT GOLD is a trademark filed by Curae Pharma360 Inc. on September 1, 2023. The trademark is classified under Class 40 (Treatment & Processing), Class 44 (Medical Services), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Curae Pharma360 Inc. (9 trademarks)

1209 ORANGE STREET
WILMINGTON, DE 19801

Entity Type: 03

Angels for Change Inc.

2408 Fountain Grass Drive
Valrico, FL 33594

Entity Type: 99

Trademark Details

Filing Date

September 1, 2023

Registration Date

December 3, 2024

Published for Opposition

September 10, 2024

Goods & Services

Consulting services in the field of pharmaceutical manufacturing, namely, generic drugs for cancer treatment

Promoting the interests of cancer patients by means of public advocacy, specifically access and availability of generic drugs for cancer treatment; Promoting public awareness of supply chain issues of generic cancer treatment drugs by means of public advocacy; Pharmaceutical cost management services and drug utilization review services, namely, generic drugs for cancer treatment; Providing advertising, marketing and promotional services for the pharmaceutical and medical industry, namely, the manufacture and distribution of generic cancer treatment drugs; Promoting public interest and awareness of availability and accessibility of generic drugs for cancer treatment; Consulting in the field of distributorship services for pharmaceuticals, namely, generic drugs for cancer treatment

Providing patient advocate services in the field of cancer treatment, namely, increasing access to and availability of generic drugs therefor; Providing patient advocate and case management services, namely, coordinating the procurement and administration of medication, specifically for generic drugs for cancer treatment; Providing information about legal eligibility requirements for government medical and pharmaceutical programs, namely, for access to and availability of generic drugs for cancer treatment

Pharmaceutical advice, namely, to facilitate and subsidize access to and availability of generic drugs for cancer treatment; Providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals, namely, generic drugs for cancer treatment

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 3, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 3, 2024 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 10, 2024 NPUB
PUBLISHED FOR OPPOSITION
Sep 10, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 21, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 6, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 6, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 6, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 6, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 6, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 5, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 5, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 5, 2024 TROA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
May 4, 2024 AAUA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 3, 2024 GNRN
NON-FINAL ACTION E-MAILED
May 3, 2024 GNRT
NON-FINAL ACTION WRITTEN
May 3, 2024 CNRT
USE AMENDMENT ACCEPTED
May 3, 2024 IUAA
ASSIGNED TO EXAMINER
Apr 30, 2024 DOCK
AMENDMENT TO USE PROCESSING COMPLETE
Feb 7, 2024 AUPC
USE AMENDMENT FILED
Feb 7, 2024 IUAF
TEAS AMENDMENT OF USE RECEIVED
Feb 6, 2024 EAAU
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 27, 2023 NWOS
NEW APPLICATION ENTERED
Sep 5, 2023 NWAP